|
|
| VGX
CEO named Among 50 Most Influential Men under 42
|
| Blue
Bell, PA – September 22, 2006 – |
|
J. Joseph Kim, Ph.D., Co-founder, President & CEO
of VGX Pharmaceuticals, has placed number 27 on a list of the "50
Most Influential Men Under 42" in the October "Power Issue"
of Details, a trendy, upscale magazine catering to the contemporary male.
This is the second time that Dr. Kim has been named to this select group
of business and political leaders as well as entertainers and other influential
men by Details. In October 2003, Dr. Kim was ranked number 38 on the same
list.
This year’s ranking was led by Actors Brad Pitt and Vince Vaughn,
followed by Chad Hurley and Steve Chen, the co-founders of entertainment
company YouTube. Other influential men include No. 20, Shawn Carter (A.K.A.
Jay-Z), 36, President & CEO of Def Jam Recordings; No. 25, Bashar
Al-Assad, 41, President of Syria; No. 31, Dan Bartlett, 35, White House
Counselor; No. 33, Ryan Seacrest, 31, Host, American Idol.
The Google Co-founders Sergei Brin and Larry Page, No. 11, are joined
by Dov Charney, No. 32, founder and CEO of American Apparel; David Lauren,
No. 21, Sr. VP of Polo Ralph Lauren; Ryan Kavanaugh No. 26, CEO of Relativity
Media; NBA Stars Lebron James and Dwayne Wade, No. 35, and US Senator
John Sununu, No. 44.
Entertainers Leonardo DiCaprio, No. 9; Stephen Colbert, No. 12; Nick Lachey,
No. 28; and Kanye West, No. 42; Kiefer Sutherland, No. 45; Dane Cook,
No. 50, also made the list.
“I am flattered to be included in this select group of people again.
I hope to continue to improve with age,” said Dr. Kim.
A co-founder of VGX Pharmaceuticals, Dr. Kim is a veteran of biopharmaceutical
industry. Prior to VGX, Dr. Kim led efforts in manufacturing and process
development of several FDA-approved products and developmental therapeutics
at Merck. These products include FDA-approved vaccines for Hepatitis as
well as developmental vaccines and therapeutics for HIV/AIDS. Dr. Kim
has published over 70 peer-reviewed scientific papers and book chapters,
holds numerous patents and sits on several editorial boards and review
panels. Dr. Kim has garnered many honors during his career. In 2002, Dr.
Kim was named as one of the world's top 100 young innovators by Technology
Review magazine. Also in 2002, Dr. Kim was chosen as one the "40
under 40" by the Philadelphia Business Journal as one of the 40 most
dynamic professionals who are under 40 years of age in the region. In
2004, Dr. Kim and VGX Pharmaceuticals were selected as one of 30 Technology
Pioneers by the World Economic Forum. Furthermore, Dr. Kim was featured
in the “Who’s Next 2005” issue of Newsweek International,
which included a group of 10 leaders, scientists, and executives at the
forefront of change and impact in the world. Most recently in 2006, Dr.
Kim has been named a Young Global Leader by the Forum of Young Global
Leaders, an affiliate of the World Economic Forum. Dr. Kim was among 175
leading executives, public figures and intellectuals under the age of
40 from 50 countries. Dr. Kim has also been featured in articles in Forbes
and the New Yorker.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About
VGX Pharmaceuticals
VGX Pharmaceuticals is a leading biopharmaceutical company with strong product
candidates for the treatment of infectious diseases including HIV and hepatitis
C virus (HCV) as well as cancer and inflammatory diseases. The Company’s
clinical development programs include PICTOVIR™ for HIV infection
and VGX-410C for chronic HCV infection, which are currently in Phase II
clinical trials. In addition, a Phase I clinical trial will be initiated
in 2007 for the Company’s lead cancer drug compound, VGX-150 for the
treatment of Melanoma. Moreover, VGX Pharmaceuticals’ therapeutic
platform is designed to advance a strong and continual pipeline of additional
drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027
and VGX-750 for inflammatory diseases currently in development. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
